According to a recent LinkedIn post from All G, the company recently exhibited for the first time in Europe at the in-cosmetics Global trade show. The post highlights that All G engaged with partners across the personal care sector, with technical discussions reportedly moving quickly into formulation details and clinical validation.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post indicates that All G showcased its recombinant lactoferrin, positioning it as a component for next-generation personal care formulations. The company suggests that conversations at the event were supported by preclinical and clinical data, implying that its offering may be further along the validation curve than early-concept ingredients.
For investors, the activity at in-cosmetics Global suggests growing commercial outreach in European personal care markets, where demand for bio-based and functional ingredients is rising. Strong technical engagement with formulators and reference to clinical data may signal a path toward higher-value applications and premium pricing potential for All G’s recombinant lactoferrin.
If these interactions translate into development partnerships or supply agreements, All G could see an expanding revenue pipeline tied to skincare and other personal care use cases. At the same time, the emphasis on clinical validation underscores the need for continued R&D investment and regulatory alignment, factors that may influence both timelines to market and margin profiles in this segment.